|1.||Breukink, Eefjan: 2 articles (01/2013 - 04/2006)|
|2.||Raffa, Demetrio: 1 article (12/2015)|
|3.||Cascioferro, Stella: 1 article (12/2015)|
|4.||Maggio, Benedetta: 1 article (12/2015)|
|5.||Schillaci, Domenico: 1 article (12/2015)|
|6.||Raimondi, Maria Valeria: 1 article (12/2015)|
|7.||Daidone, Giuseppe: 1 article (12/2015)|
|8.||Lu, Wuyuan: 1 article (01/2013)|
|9.||Varney, Kristen M: 1 article (01/2013)|
|10.||Oashi, Taiji: 1 article (01/2013)|
09/01/2009 - "Our results also indicate that the lipid II pathway may be exploited as an antibacterial target for chlamydial and filarial infections."
12/10/2015 - "Sortase A is involved in the process of bacterial adhesion by anchoring LPXTG-containing proteins to lipid II. Sortase A inhibitors do not affect bacterial growth, but they restrain the virulence of pathogenic bacterial strains, thereby preventing infections caused by Staphylococcus aureus or other Gram-positive bacteria. "
12/01/2006 - "Ramoplanin, a novel antibiotic with activity against aerobic and anaerobic gram-positive bacteria, acts to prevent cell wall peptidoglycan formation by binding to a key intermediate moiety, lipid II. It has been fast-tracked by the US FDA for the prevention of enterococcal infections and the treatment of Clostridium difficile. "
07/01/2004 - "These virulence-associated proteins generally contain a C-terminal LPXTG motif that becomes covalently anchored to the peptidoglycan biosynthesis intermediate lipid II. In Staphylococcus aureus, deletion of the sortase isoform SrtA results in marked reduction in virulence and infection potential, making it an important antivirulence target. "
01/01/2013 - "Based on the complex of Lipid II with Human Neutrophil peptide-1, we could identify and characterize chemically diverse low-molecular weight compounds that mimic the interactions between HNP-1 and Lipid II. Lead compound BAS00127538 was further characterized structurally and functionally; it specifically interacts with the N-acetyl muramic acid moiety and isoprenyl tail of Lipid II, targets cell wall synthesis and was protective in an in vivo model for sepsis. "
09/01/1988 - "Characterization of these derivatives revealed that they were defective in various steps of ECA synthesis leading to the synthesis of lipid II. The data support the conclusion that accumulation of lipid II is responsible in some way for the hypersensitivity of delta rfbA mutants to SDS."
|5.||Bacterial Infections (Bacterial Infection)
04/01/2006 - "However, the growing problem of bacterial resistance to many current drugs, including vancomycin, has led to increasing interest in the therapeutic potential of other classes of compound that target Lipid II. Here, we review progress in understanding of the antibacterial activities of these compounds, which include lantibiotics, mannopeptimycins and ramoplanin, and consider factors that will be important in exploiting their potential as new treatments for bacterial infections."
|2.||Proteins (Proteins, Gene)
|6.||Muramic Acids (Muramic Acid)
|9.||human neutrophil peptide 1